AstraZeneca (($AZN)) announced an update on their ongoing clinical study. In a recent update, AstraZeneca announced a new clinical study titled ...

Neurofibromatosis is a group of rare genetic disorders that cause benign tumors to form on nerve tissue. Tumors in this disorder are usually noncancerous (benign), but can sometimes become cancerous ...

No, your eyes aren't playing tricks on you. There really were a few dozen scantily-clad runners making their way down Division Street on Saturday afternoon. The group was baring almost all for a good ...

Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin, nervous system, and other parts of the body. The condition, formerly called Von Recklinghausen disease, causes changes in ...

Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

Investing.com -- AstraZeneca PLC (ST:AZN) announced Tuesday that its drug Koselugo (selumetinib) has received European Union ...

INDIANAPOLIS — A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral challenges associated with neurofibromatosis type 1, or NF1 ...

Caleb McLaughlin, 8, of the Center Grove area holds a sign marking the route for Walk4NF, a fundraiser and community event for NF Midwest, on May 17 at White River State Park. Caleb has ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on nerves throughout the body. The federal agency said on Tuesday it ...

On the outside, Yoseph Williamson looks like a typical 14-year-old. He’s a personable kid with an easy smile and a curious mind. But lying beneath his skin are a number of painful tumors from a ...